JW Pharmaceutical Receives 3-Month Sales Suspension for 31 Drugs
-
Subsidiary JW Pharmaceutical received 3-month sales suspension for 31 drug items (May 6 to Aug 5, 2026) due to violation of Pharmaceutical Affairs Act
-
Suspension amount: 53.5 billion KRW, 6.91% of recent sales (775.3 billion KRW)
-
Encover Liquid fined 285.3 million KRW in lieu of suspension
-
Company expects minimal impact on annual sales
KOSPI Filing Information
-
Filing: Report on Material Fact (Suspension of Business) (Major Management Matters of Subsidiary)
-
Company: JW Holdings (096760)
-
Submission: JW Holdings Corporation
-
Receipt: 04-30-2026
-
Under KRX KOSPI Market Division